Navigation Links
MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
Date:3/4/2008

-

Depreciation and amortization 4,460,069 3,919,267

Warrant expense 2,100,000 -

Stock-based compensation 1,931,439 3,404,063

Deferred rent and credit on lease

concession (75,060) (15,957)

Amortization of premium on

marketable securities (39,687) 204,525

(Gain) or loss on disposal of fixed

assets - 23,185

Advance payment for sale of Keflex - (1,000,000)

Changes in:

Accounts receivable (384,273) 574,751

Inventories 1,389,457 (1,857,939)

Prepaid expenses and other current

assets 539,780 (885,432)

Deposits other than on property

and equipment 304,151 (30,096)

Accounts payable (625,984) 599,249

Accrued expenses and advances (2,260,048) 534,236

Deferred product and contract revenue (189,000) 189,000

Net cash used in operating

activities (35,260,711) (36,331,302)

Cash flows from investing activities:

Purchase of marketable securities (5,867,519) (13,764,736)

Sale and maturities of marketable

securities 6,430,000 24,355,000

Purchases of property and equipment (1,396,954) (300,929)

Deposits on property and equipment - (250,000)

Proceeds from sale of fixed assets - 25,000

Change i
'/>"/>

SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million
2. MiddleBrook Pharmaceuticals to Present at BIO CEO & Investor Conference 2008
3. MiddleBrook Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 4, 2008
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... 2015 Cutting-edge biotech & ... nutrition products reveal technological advancements are in growing ... as hyperglycemia, obesity, insulin level issues and other ... Companies in focus today are: RiceBran Technologies (NASDAQ: ... ANFI ), CEL-SCI Corporation (NYSE: ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 Sterlitech is ... flat-sheet testing system at the 2015 AMTA Membrane Technology ... culmination of a decade’s worth of engineering and customer ... with a wide range of applications across an array ... enough to meet the dynamic needs of researchers and ...
(Date:2/28/2015)... Increasing its efforts to resolve the GMO Controversy ... of The GMO TRUTH podcast on both ITunes and at ... its mission to discover the truth and change the world. ... the truth about the GMOs in our food supply,” adds ... is an expansion of the documentary/investigative film-making methodology in place ...
(Date:2/27/2015)... , Feb. 27, 2015 A ... the NCATS rare-diseases portfolio " in Science ... new financing technique to reduce the risk associated ... and potentially unlock new levels of funding for ... product of a unique collaboration between scientists at ...
Breaking Biology Technology:Clinical Studies & Research Substantiate Claims That Company's Targeted Healthy Nutritional Products Promote Healthy Lipids, Glucose & Insulin Levels 2Clinical Studies & Research Substantiate Claims That Company's Targeted Healthy Nutritional Products Promote Healthy Lipids, Glucose & Insulin Levels 3Clinical Studies & Research Substantiate Claims That Company's Targeted Healthy Nutritional Products Promote Healthy Lipids, Glucose & Insulin Levels 4Clinical Studies & Research Substantiate Claims That Company's Targeted Healthy Nutritional Products Promote Healthy Lipids, Glucose & Insulin Levels 5Clinical Studies & Research Substantiate Claims That Company's Targeted Healthy Nutritional Products Promote Healthy Lipids, Glucose & Insulin Levels 6Clinical Studies & Research Substantiate Claims That Company's Targeted Healthy Nutritional Products Promote Healthy Lipids, Glucose & Insulin Levels 7Sterlitech Displays Complete CF042 Membrane Test System 2The Walk a Mile Project Launches “GMO Truth” Podcast 2New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 2New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 3New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 4
... Oct. 10 DermTech International, Inc.,a biotechnology ... early,detection of melanoma and other diseases, today ... Advisory Board. Dr. Quackenbush is a,Professor of ... Institute and Professor of Computational Biology and ...
... For Hispanic-Americans without health,insurance, it can be difficult ... prescription medicines. However, help is available for people,who ... doctors. Listen to this report from Pfizer ... Registered journalists can access video, audio, text, graphics ...
... MISSISSAUGA, ON, Oct. 9 /PRNewswire-FirstCall/ - Vasogen Inc.,(NASDAQ: VSGN ... the,third quarter of 2007. All dollar amounts referenced herein ... 31, 2007, our cash and cash equivalents and restricted ... 31, 2007. With,the repayment of our convertible notes during ...
Cached Biology Technology:DermTech Appoints BioStatistical Pioneer, John Quackenbush, Ph.D., as a Member of the Company's Scientific Advisory Board 2Vasogen Announces Third Quarter 2007 Results 2Vasogen Announces Third Quarter 2007 Results 3Vasogen Announces Third Quarter 2007 Results 4Vasogen Announces Third Quarter 2007 Results 5Vasogen Announces Third Quarter 2007 Results 6Vasogen Announces Third Quarter 2007 Results 7Vasogen Announces Third Quarter 2007 Results 8Vasogen Announces Third Quarter 2007 Results 9Vasogen Announces Third Quarter 2007 Results 10Vasogen Announces Third Quarter 2007 Results 11Vasogen Announces Third Quarter 2007 Results 12Vasogen Announces Third Quarter 2007 Results 13
(Date:3/2/2015)... , March 2, 2015 Synaptics Inc. ... of human interface solutions, today announced a new ... designed to enable rapid and secure transactions and ... for gaming is a turnkey solution providing mouse ... to quickly integrate fingerprint ID solutions into their ...
(Date:3/2/2015)... HUNTSVILLE, Ala. , March 2, 2015 /PRNewswire/ ... transaction processing. Data protection company Tharon Rankins Enterprises ... product that provides an ultra-safe way for businesses ... as their financial transactions. Beconux ... by Tharon Rankins Enterprises. Functioning similarly to an ...
(Date:3/2/2015)...   Neurotechnology , a provider of high-precision biometric, ... Software Development Kit (SDK). The SentiGaze algorithm enables ... webcams to track eye movements and generate heatmaps based ... can be used for applications such as analysis of ... SDK can also be used to develop interfaces for ...
Breaking Biology News(10 mins):Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3Personal Data Protection Company Launches New Product 2Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 2Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 3
... Tri-Band WLAN Module in SDIO Card Form Factor, ... today,announced the SX-SDWAG, the first world,s first wireless ... form factor. Designed for,wireless local area network (WLAN) ... ideal for battery-operated portable devices in,the medical, weights ...
... consolidating world databases of ocean organisms have demoted ... culled from 34 regional and highly specialized inventories. ... ( www.marinespecies.org ) contains about 122,500 validated marine ... some 56,400 aliases 32% of all names ...
... Calif.) Michael Gazzaniga, professor of psychology at UC ... the Study of the Mind, has received the Humboldt ... "Professor Gazzaniga is a true pioneer in reaching ... the relationship between mind and brain," said UCSB Chancellor ...
Cached Biology News:Silex Introduces SX-SDWAG 802.11a/b/g SDIO Radio Card for OEM Portable Device Applications 2Census of Marine Life lists 122,500 known species, over halfway to complete inventory by Oct. 2010 2Census of Marine Life lists 122,500 known species, over halfway to complete inventory by Oct. 2010 3Census of Marine Life lists 122,500 known species, over halfway to complete inventory by Oct. 2010 4Census of Marine Life lists 122,500 known species, over halfway to complete inventory by Oct. 2010 5Neuroscientist Michael Gazzaniga awarded Humboldt Prize 2
This application changes sensitive keywords in an FCS file to remove patient information. It was contributed by Dr. David Miller....
... Killer Cell Receptor-P1, clone 1C10 ... Hybridoma produced by the ... mice immunized (BALB/c X C57BL/6)F1 ... and mouse myeloma cellline. ...
Phospho-SEK1/MKK4 (Thr261) Antibody...
Rabbit polyclonal to Warfarin ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule conjugated to KLH...
Biology Products: